| Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis B Uzzan, J Campos, M Cucherat, P Nony, JP Boissel, GY Perret The Journal of Clinical Endocrinology & Metabolism 81 (12), 4278-4289, 1996 | 606 | 1996 |
| Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease F Bonnet, K Irving, JL Terra, P Nony, F Berthezène, P Moulin Atherosclerosis 178 (2), 339-344, 2005 | 604 | 2005 |
| Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of … L Pinede, J Ninet, P Duhaut, S Chabaud, S Demolombe-Rague, I Durieu, ... Circulation 103 (20), 2453-2460, 2001 | 495 | 2001 |
| The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use JP Boissel, M Cucherat, W Li, G Chatellier, F Gueyffier, M Buyse, ... Therapie 54 (4), 405-411, 1999 | 373 | 1999 |
| The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 E Erhardtsen, P Nony, M Dechavanne, P Ffrench, JP Boissel, U Hedner Blood coagulation & fibrinolysis 9 (8), 741-748, 1998 | 212 | 1998 |
| Phosphodiesterase III inhibitors for heart failure E Amsallem, C Kasparian, G Haddour, JP Boissel, P Nony Cochrane Database of Systematic Reviews, 2005 | 166 | 2005 |
| Depressive symptoms are associated with unhealthy lifestyles in hypertensive patients with the metabolic syndrome F Bonnet, K Irving, JL Terra, P Nony, F Berthezène, P Moulin Journal of hypertension 23 (3), 611-617, 2005 | 137 | 2005 |
| Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis P Nony, JP Boissel, M Lievre, A Leizorovicz, MC Haugh, S Fareh, ... European journal of clinical pharmacology 46, 191-196, 1994 | 136 | 1994 |
| A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at … MR Skilton, P Moulin, A Sérusclat, P Nony, F Bonnet Atherosclerosis 190 (2), 416-422, 2007 | 126 | 2007 |
| Experimental designs for small randomised clinical trials: an algorithm for choice C Cornu, B Kassai, R Fisch, C Chiron, C Alberti, R Guerrini, A Rosati, ... Orphanet journal of rare diseases 8, 1-12, 2013 | 123 | 2013 |
| Investigators of the “Durée Optimale du Traitement AntiVitamines K”(DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal … L Pinede, J Ninet, P Duhaut, S Chabaud, S Demolombe-Rague, I Durieu, ... Circulation 103 (20), 2453-2460, 2001 | 93 | 2001 |
| A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms C Cornu, C Mercier, T Ginhoux, S Masson, J Mouchet, P Nony, B Kassai, ... European child & adolescent psychiatry 27, 377-384, 2018 | 64 | 2018 |
| A pharmacokinetic simulation model for ivabradine in healthy volunteers SB Duffull, S Chabaud, P Nony, C Laveille, P Girard, L Aarons European journal of pharmaceutical sciences 10 (4), 285-294, 2000 | 61 | 2000 |
| Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris S Chabaud, P Girard, P Nony, JP Boissel Journal of pharmacokinetics and pharmacodynamics 29, 339-363, 2002 | 56 | 2002 |
| Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol P Girard, P Nony, E Erhardtsen, S Delair, P Ffrench, M Dechavanne, ... Thrombosis and haemostasis 80 (07), 109-113, 1998 | 55 | 1998 |
| Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance JP Boissel, P Nony Clinical pharmacokinetics 41, 1-6, 2002 | 54 | 2002 |
| Model of mucociliary clearance in cystic fibrosis lungs P Kurbatova, N Bessonov, V Volpert, H Tiddens, C Cornu, P Nony, ... Journal of theoretical biology 372, 81-88, 2015 | 52 | 2015 |
| In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates S Goutelle, L Bourguignon, N Bleyzac, J Berry, F Clavel-Grabit, M Tod, ... The AAPS journal 15, 415-426, 2013 | 46 | 2013 |
| Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation JP Boissel, E Amsallem, M Cucherat, P Nony, MC Haugh European journal of clinical pharmacology 60, 609-616, 2004 | 44 | 2004 |
| A physiologically based pharmacokinetic model for Valproic acid in adults and children K Ogungbenro, L Aarons European Journal of Pharmaceutical Sciences 63, 45-52, 2014 | 40 | 2014 |
